PhaseBio Pharmaceuticals Employee Directory

PhaseBio Pharmaceuticals corporate office is located in 1 Great Valley Pkwy Ste 30, Malvern, Pennsylvania, 19355, United States and has 51-200 employees.

PhaseBio Pharmaceuticals Global Presence

globalPresence illustration
North America1-10

PhaseBio Pharmaceuticals CEO

JM
United States flag for contact location.
Jonathan MowChief Executive Officer
PhonePhoneEmailEmail
See Profile

Key Employees of PhaseBio Pharmaceuticals

  • JE
    United States flag for contact location.
    June Edgerton

    Office Manager

    PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail

Index of contact profiles from PhaseBio Pharmaceuticals

Hundreds of professionals searching for PhaseBio Pharmaceuticals have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
12

Former Employees at PhaseBio Pharmaceuticals

Explore people who held key positions, contributed to PhaseBio Pharmaceuticals's success, and advanced their careers.

People from Similar Companies in the Manufacturing Industry Located in Pennsylvania, United States

Frequently Asked Questions Regarding PhaseBio Pharmaceuticals Employees

How many employees does PhaseBio Pharmaceuticals have?
PhaseBio Pharmaceuticals has 51-200 employees
Who is the CEO of PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals’s CEO is Jonathan Mow
Who are PhaseBio Pharmaceuticals key employees?
Some of PhaseBio Pharmaceuticals key employees are June Edgerton
Where is PhaseBio Pharmaceuticals located?
PhaseBio Pharmaceuticals’s headquarters are located at 1 Great Valley Pkwy Ste 30, Malvern, Pennsylvania, 19355, United States
How do I contact PhaseBio Pharmaceuticals?
PhaseBio Pharmaceuticals Contact Info: Phone number: (610) 981-6500 Website: www.phasebio.com
What does PhaseBio Pharmaceuticals do?

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat cardiopulmonary diseases. The company's lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-li... ke polypeptide ("ELP") technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio's second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension.Read More

Is PhaseBio Pharmaceuticals a public company?
Yes, PhaseBio Pharmaceuticals is a public company and is traded under the symbol PHAS
See more information about PhaseBio Pharmaceuticals Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.